Best AI Index Fund to Buy
Over the last two years, companies with a focus on…
Buy
55
BMY Quote, Financials, Valuation and Earnings
Last price:
$48.26
Seasonality move
:
0.81%
Day range:
$47.30 - $48.35
52-week range:
$39.35 - $63.33
Dividend yield:
5.05%
P/E ratio:
18.08x
P/S ratio:
2.06x
P/B ratio:
5.65x
Volume:
20.8M
Avg. volume:
16.2M
1-year change:
19.95%
Market cap:
$98.3B
Revenue:
$48.3B
EPS (TTM):
$2.67
Analysts' Opinion
-
Consensus RatingBristol-Myers Squibb has received a consensus rating of Hold. The company's average rating is a Hold based on 4 Buy ratings, 18 Hold ratings, and 1 Sell rating.
-
Price Target UpsideAccording to analysts' consensus price target of $56.96, Bristol-Myers Squibb has an estimated upside of 17.98% from its current price of $48.28.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $36.00 representing 25.44% downside risk from its current price of $48.28.
Fair Value
-
According to the consensus of 23 analysts, Bristol-Myers Squibb has 17.98% upside to fair value with a price target of $56.96 per share.
BMY vs. S&P 500
-
Over the past 5 trading days, Bristol-Myers Squibb has overperformed the S&P 500 by 0.77% suggesting its relative strength compared to the major market average is strong at this time.
Share Buyback
-
Bristol-Myers Squibb does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Bristol-Myers Squibb revenues have been falling on a year-over-year basis for 1 quarter in a row. In the most recent quarter Bristol-Myers Squibb reported revenues of $11.2B.
Earnings Growth
-
Bristol-Myers Squibb earnings have been falling on a year-over-year basis for 3 quarters in a row. In the most recent quarter Bristol-Myers Squibb reported earnings per share of $1.20.
Enterprise value:
136.2B
EV / Invested capital:
--
Price / LTM sales:
2.06x
EV / EBIT:
16.77x
EV / Revenue:
2.86x
PEG ratio (5yr expected):
--
EV / Free cash flow:
10.41x
Price / Operating cash flow:
7.50x
Enterprise value / EBITDA:
8.41x
Gross Profit (TTM):
$33.6B
Return On Assets:
5.74%
Net Income Margin (TTM):
11.38%
Return On Equity:
32.01%
Return On Invested Capital:
7.93%
Operating Margin:
31.22%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-03-31 | 2024-03-31 | 2025-03-31 | 2024-03-31 | 2025-03-31 | |
| Income Statement | ||||||
| Revenue | $45.8B | $45.5B | $47.6B | $11.9B | $11.2B | |
| Gross Profit | $35.6B | $34.5B | $33.6B | $8.9B | $8.2B | |
| Operating Income | $8.9B | $7.3B | $7.9B | $1.5B | $3.5B | |
| EBITDA | $20.1B | $5.3B | $16.2B | -$8.6B | $4.5B | |
| Diluted EPS | $3.43 | -$3.10 | $2.67 | -$5.89 | $1.20 | |
| Period Ending | 2021-03-31 | 2022-03-31 | 2023-03-31 | 2024-03-31 | 2025-03-31 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $27.1B | $30.1B | $27.1B | $28.7B | $30.8B | |
| Total Assets | $112.4B | $103B | $94.3B | $99B | $92.4B | |
| Current Liabilities | $17.3B | $22.8B | $19.1B | $25.8B | $24.1B | |
| Total Liabilities | $74.8B | $71.4B | $62.4B | $82.5B | $75B | |
| Total Equity | $37.7B | $31.6B | $31.9B | $16.5B | $17.4B | |
| Total Debt | $46.3B | $45B | $37.8B | $55.7B | $49.7B | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-03-31 | 2024-03-31 | 2025-03-31 | 2024-03-31 | 2025-03-31 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | $12.2B | $13.7B | $14.3B | $2.8B | $2B | |
| Cash From Investing | -$1.4B | -$21.7B | -$2.2B | -$19.6B | -$499M | |
| Cash From Financing | -$14.4B | $8.3B | -$10.5B | $14.6B | -$993M | |
| Free Cash Flow | $11.1B | $12.5B | $13.1B | $2.6B | $1.7B | |
BMY
Sector
Market Cap
$98.3B
$33.4M
Price % of 52-Week High
76.24%
45.25%
Dividend Yield
5.05%
0%
Shareholder Yield
2.14%
-0.66%
1-Year Price Total Return
19.95%
-40%
Beta (5-Year)
0.392
0.653
Dividend yield:
5.05%
Annualized payout:
$2.40
Payout ratio:
90.59%
Growth streak:
3 years
Technicals
8-day SMA
Buy
Level
$47.34
200-day SMA
Sell
Level
$54.00
Bollinger Bands (100)
Sell
Level
49.56 - 59.64
Chaikin Money Flow
Buy
Level
798.5M
20-day SMA
Buy
Level
$47.33
Relative Strength Index (RSI14)
Sell
Level
49.50
ADX Line
Sell
Level
31.63
Williams %R
Sell
Level
-3.0621
50-day SMA
Sell
Level
$51.28
MACD (12, 26)
Sell
Level
-0.90
25-day Aroon Oscillator
Sell
Level
-32
On Balance Volume
Neutral
Level
605.1M
Financial Scores
Sell
Altman Z-Score
(Annual)
Level (1.4991)
Sell
CA Score
(Annual)
Level (-1.7489)
Buy
Beneish M-Score
(Annual)
Level (-3.72)
Buy
Momentum Score
Level (8)
Buy
Ohlson Score
Level (-0.0559)
Buy
Piotroski F Score
(Annual)
Level (4)
Buy
Quality Ratio Score
Level (5)
Buy
Fundamental Score
Level (7)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Bristol derives close to 70% of total sales from the US, showing a higher dependence on the US market than most of its peer group.
Stock Forecast FAQ
In the current month, BMY has received 4 Buy ratings 18 Hold ratings, and 1 Sell ratings. The BMY average analyst price target in the past 3 months is $56.96.
-
Where Will Bristol-Myers Squibb Stock Be In 1 Year?
According to analysts, the consensus estimate is that Bristol-Myers Squibb share price will rise to $56.96 per share over the next 12 months.
-
What Do Analysts Say About Bristol-Myers Squibb?
Analysts are divided on their view about Bristol-Myers Squibb share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Bristol-Myers Squibb is a Sell and believe this share price will drop from its current level to $36.00.
-
What Is Bristol-Myers Squibb's Price Target?
The price target for Bristol-Myers Squibb over the next 1-year time period is forecast to be $56.96 according to 23 Wall Street analysts, 4 of them rate the stock a Buy, 1 rates the stock a Sell, and 18 analysts rate the stock a Hold.
-
Is BMY A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Bristol-Myers Squibb is a Hold. 18 of 23 analysts rate the stock a Hold at this time.
-
How Can I Buy Shares Of BMY?
You can purchase shares of Bristol-Myers Squibb via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, tastytrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Bristol-Myers Squibb shares.
-
What Is The Bristol-Myers Squibb Share Price Today?
Bristol-Myers Squibb was last trading at $48.26 per share. This represents the most recent stock quote for Bristol-Myers Squibb. Yesterday, Bristol-Myers Squibb closed at $48.28 per share.
-
How To Buy Bristol-Myers Squibb Stock Online?
In order to purchase Bristol-Myers Squibb stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Where Will Salesforce Stock Be in 5 Years?
Salesforce (NYSE: CRM) just turned in a quarter that, on…
2 Ultra Safe Dividend Stocks to Buy Now
Historically, blue-chip dividend stocks have been good choices for periods…
Stock Ideas
Buy
67
Is MSFT Stock a Buy?
Market Cap: $3.4T
P/E Ratio: 39x
Buy
65
Is NVDA Stock a Buy?
Market Cap: $3.3T
P/E Ratio: 46x
Sell
40
Is AAPL Stock a Buy?
Market Cap: $3T
P/E Ratio: 33x
Alerts
Sell
31
REGN alert for May 31
Regeneron Pharmaceuticals [REGN] is down 19.04% over the past day.
Buy
55
RGC alert for May 31
Regencell Bioscience Holdings [RGC] is up 16.13% over the past day.
Sell
42
AMBA alert for May 31
Ambarella [AMBA] is down 15.13% over the past day.
